ChiCTR2100052619 版本V1.1 版本创建时间2022/04/29 13:52:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052619 

最近更新日期:

Date of Last Refreshed on:

2021-11-02 19:35:06 

注册时间:

Date of Registration:

2021-11-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

评价30%超分子水杨酸联合超分子活性锌治疗马拉色菌毛囊炎的有效性和安全性临床研究

Public title:

Evaluation of efficacy and safety of 30% supramolecular salicylic acid combined with supramolecular active zinc in the treatment of Malassezia Folliculitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

评价30%超分子水杨酸联合超分子活性锌治疗马拉色菌毛囊炎的有效性和安全性临床研究

Scientific title:

Evaluation of efficacy and safety of 30% supramolecular salicylic acid combined with supramolecular active zinc in the treatment of Malassezia Folliculitis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘振峰 

研究负责人:

刘振峰 

Applicant:

Liu Zhen Feng 

Study leader:

Liu Zhen Feng 

申请注册联系人电话:

Applicant telephone:

18011788797

研究负责人电话:

Study leader's telephone:

18011788797

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuzhenfengpuma@163.com

研究负责人电子邮件:

Study leader's E-mail:

liuzhenfengpuma@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区麓景路2号

研究负责人通讯地址:

广东省广州市越秀区麓景路2号

Applicant address:

No.2 Lujing Road, Yuexiu District, Guangzhou, Guangdong

Study leader's address:

No.2 Lujing Road, Yuexiu District, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学皮肤病医院

Applicant's institution:

Dermatology Hospital of Southern Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021061

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学皮肤病医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Dermatology Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

吕萍

Contact Name of the ethic committee:

Lv Ping

伦理委员会联系地址:

广东省广州市越秀区麓景路2号

Contact Address of the ethic committee:

No.2 Lujing Road, Yuexiu District, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学皮肤病医院

Primary sponsor:

Dermatology Hospital of Southern Medical University

研究实施负责(组长)单位地址:

广东省广州市越秀区麓景路2号

Primary sponsor's address:

No.2 Lujing Road, Yuexiu District, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学皮肤病医院

具体地址:

越秀区麓景路2号

Institution
hospital:

Dermatology Hospital of Southern Medical University

Address:

2 Lujing Road, Yuexiu District

经费或物资来源:

上海瑞志医药科技有限公司临床研究项目基金

Source(s) of funding:

Clinical Study Fund of Shanghai Ruizhi Medical Technology Co., LTD

Target disease:

Malassezia Folliculitis

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

评价30%超分子水杨酸联合超分子活性锌治疗马拉色菌毛囊炎的有效性和安全性  

Objectives of Study:

To evaluate the efficacy and safety of 30% supramolecular salicylic acid combined with supramolecular active zinc in the treatment of Malassezia Folliculitis

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、入选标准:
1) 男女不限,年龄为18~65周岁;
2)经检测为马拉色菌毛囊炎者;
3) 发生在前胸或后背的Ⅱ~Ⅲ级毛囊炎。
Ⅱ级为中等量凸起的丘疹、脓疱、丘脓疱疹,总皮损数30~50个;
Ⅲ级为大量凸起的丘疹、脓疱、丘脓疱疹,总皮损数50~100个;
4) 自愿参加且签署知情同意书。

Inclusion criteria

1. Inclusion criteria:
1) No gender restriction, age between 18-65 years old;
2)Tested as malassezia folliculitis patients.
3) Grade II ~ III folliculitis occurred in the front chest or back.
Grade II is moderate convex papules, pustules and mound pustules, with a total number of 30 ~ 50 lesions;
Grade III is a large number of raised papules, pustules and mound pustules, with a total number of 50 ~ 100 lesions;
4) Voluntarily participate and sign informed consent.

排除标准:

2、排除标准:
1)患有可能引起病情加重的其它皮肤疾病,或研究者认为此疾病可能影响对试验结果的判断;
2)对试验产品过敏者或高敏体质;
3)妊娠、哺乳期患者;
4)试验前4个月内口服抗真菌药物(或2个月内外用过抗真菌药物)的患者;4周内口服抗生素类、糖皮质激素类以及其他治疗毛囊炎药物的患者;或使用过物理治疗毛囊炎的患者;或经水杨酸和果酸治疗的患者;或2周内使用过外用的其他治疗毛囊炎的药物的患者;
5)试验前2个月有患处注射或手术史的患者;
6)免疫缺陷性疾病患者。

Exclusion criteria:

2. Exclusion criteria:
1) Suffering from other skin diseases that may aggravate the condition, or the researcher believes that this disease may affect the judgment of the test results.
2) Those who are allergic to the test drug or have high sensitivity.
3) Pregnant and lactating patients;
4) Subject who took oral antifungal drugs within 4 months in prior of the test (or used antifungal drugs within 2 months); Subjects with oral antibiotics, glucocorticoids and other drugs for folliculitis within 4 weeks; Or subjects who have used physical therapy for folliculitis; Or subjects treated with salicylic acid and fruit acid; Or subjects who have used other topical drugs for the treatment of folliculitis within 2 weeks;
5) Subjects with a history of injection or surgery in the affected area 2 months before the test;
6) Subjects with immune deficiency diseases.

研究实施时间:

Study execute time:

From 2021-06-01 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-15 00:00:00 To 2022-03-15 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

240

Group:

Experimental group

Sample size:

干预措施:

30%超分子水杨酸+超分子活性锌

干预措施代码:

Intervention:

30% supramolecular salicylic acid+supramolecular active zinc

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

南方医科大学皮肤病医院 

单位级别:

三级甲等 

Institution
hospital:

Dermatology Hospital of Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

皮损计数

指标类型:

主要指标

Outcome:

Skin lesion count

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

马拉色菌镜检

指标类型:

主要指标

Outcome:

Malassezia microscopic examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

复发率

指标类型:

次要指标

Outcome:

Recurrence rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者自我评价

指标类型:

次要指标

Outcome:

Patient self-evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

non-randomized

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

病例记录表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Case Report Form

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Report Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-02 19:35:01